Allan E Rodríguez1, Amanda D Castel, Carrigan L Parish, Sarah Willis, Daniel J Feaster, Michael Kharfen, Gabriel A Cardenas, Kira Villamizar, Michael Kolber, Liliana Vázquez-Rivera, Lisa R Metsch. 1. *Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida; †Department of Epidemiology and Biostatistics, George Washington University, Washington, D.C.; ‡Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York; §Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida; ‖District of Columbia Department of Health, HIV/AIDS, Hepatitis, STD, and TB Administration, Washington, D.C.; and ¶Miami-Dade County Health Department, Office of HIV/AIDS Services, Miami, Florida.
Abstract
INTRODUCTION: In 2005, the Centers for Disease Control and Prevention expanded its recommendation of postexposure prophylaxis (PEP) use in the workplace to include nonoccupational exposures (nPEP). The availability and extensive use of nPEP have not achieved widespread acceptance among health-care providers of high-risk populations, and public health and primary care agencies have been sparse in their implementation of nPEP promotion, protocols, and practices. METHODS: We conducted a survey of HIV providers (n = 142, response rate = 61%) in Miami-Dade County (Florida) and the District of Columbia that focused on their knowledge, attitudes, beliefs, and practices related to the delivery of nPEP. We then analyzed differences in survey responses by site and by history of prescribing nPEP using bivariate and multivariate logistic regression. RESULTS: More District of Columbia providers (59.7%) reported ever prescribing nPEP than in Miami (39.5%, P < 0.048). The majority of practices in both cities did not have a written nPEP protocol and rarely or never had patients request nPEP. Multivariable analysis for history of prescribing nPEP was dominated by having patients request nPEP [odds ratio (OR) = 21.53] and the belief that nPEP would lead to antiretroviral resistance (OR = 0.14) and having a written nPEP protocol (OR = 7.49). DISCUSSION: Our findings are consistent with earlier studies showing the underuse of nPEP as a prevention strategy. The significance of having a written nPEP protocol and of patient requests for nPEP speaks to the importance of using targeted strategies to promote widespread awareness of the use of HIV antiretroviral medications as a prevention intervention.
INTRODUCTION: In 2005, the Centers for Disease Control and Prevention expanded its recommendation of postexposure prophylaxis (PEP) use in the workplace to include nonoccupational exposures (nPEP). The availability and extensive use of nPEP have not achieved widespread acceptance among health-care providers of high-risk populations, and public health and primary care agencies have been sparse in their implementation of nPEP promotion, protocols, and practices. METHODS: We conducted a survey of HIV providers (n = 142, response rate = 61%) in Miami-Dade County (Florida) and the District of Columbia that focused on their knowledge, attitudes, beliefs, and practices related to the delivery of nPEP. We then analyzed differences in survey responses by site and by history of prescribing nPEP using bivariate and multivariate logistic regression. RESULTS: More District of Columbia providers (59.7%) reported ever prescribing nPEP than in Miami (39.5%, P < 0.048). The majority of practices in both cities did not have a written nPEP protocol and rarely or never had patients request nPEP. Multivariable analysis for history of prescribing nPEP was dominated by having patients request nPEP [odds ratio (OR) = 21.53] and the belief that nPEP would lead to antiretroviral resistance (OR = 0.14) and having a written nPEP protocol (OR = 7.49). DISCUSSION: Our findings are consistent with earlier studies showing the underuse of nPEP as a prevention strategy. The significance of having a written nPEP protocol and of patient requests for nPEP speaks to the importance of using targeted strategies to promote widespread awareness of the use of HIV antiretroviral medications as a prevention intervention.
Authors: T L Katzenstein; E Dickmeiss; H Aladdin; A Hede; C Nielsen; H Nielsen; L B Jørgensen; J Gerstoft Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: Andrew C Voetsch; James D Heffelfinger; Elin B Begley; Krishna Jafa-Bhushan; Patrick S Sullivan Journal: J Acquir Immune Defic Syndr Date: 2007-11-01 Impact factor: 3.731
Authors: R S Sperling; D E Shapiro; R W Coombs; J A Todd; S A Herman; G D McSherry; M J O'Sullivan; R B Van Dyke; E Jimenez; C Rouzioux; P M Flynn; J L Sullivan Journal: N Engl J Med Date: 1996-11-28 Impact factor: 91.245
Authors: Jeffrey N Martin; Michelle E Roland; Torsten B Neilands; Melissa R Krone; Joshua D Bamberger; Robert P Kohn; Margaret A Chesney; Karena Franses; James O Kahn; Thomas J Coates; Mitchell H Katz Journal: AIDS Date: 2004-03-26 Impact factor: 4.177
Authors: D M Cardo; D H Culver; C A Ciesielski; P U Srivastava; R Marcus; D Abiteboul; J Heptonstall; G Ippolito; F Lot; P S McKibben; D M Bell Journal: N Engl J Med Date: 1997-11-20 Impact factor: 91.245
Authors: Kenneth H Mayer; Matthew J Mimiaga; Daniel Cohen; Chris Grasso; Ronn Bill; Rodney Van Derwarker; Alvan Fisher Journal: J Acquir Immune Defic Syndr Date: 2008-04-01 Impact factor: 3.731
Authors: Matthew R Beymer; Ryan M Kofron; Chi-Hong Tseng; Robert K Bolan; Risa P Flynn; Jennifer M Sayles; Mario J Perez; Wilbert C Jordan; Raphael J Landovitz Journal: Int J STD AIDS Date: 2017-11-29 Impact factor: 1.359
Authors: Kirk D Henny; Christopher C Duke; Angelica Geter; Zaneta Gaul; Chantell Frazier; Jennifer Peterson; Kate Buchacz; Madeline Y Sutton Journal: AIDS Behav Date: 2019-11
Authors: Alan E Greenberg; David W Purcell; Christopher M Gordon; Rebecca J Barasky; Carlos del Rio Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Alan E Greenberg; David W Purcell; Christopher M Gordon; Stephen Flores; Cynthia Grossman; Holly H Fisher; Rebecca J Barasky Journal: J Acquir Immune Defic Syndr Date: 2013-11-01 Impact factor: 3.731
Authors: Jeremy Fagan; Victoria Frye; Rose Calixte; Sachin Jain; Lovely Molla; Adeola Lawal; Marcus P Mosley; Emily Greene; Kenneth H Mayer; Barry S Zingman Journal: AIDS Behav Date: 2020-12
Authors: Amanda D Castel; Daniel J Feaster; Wenze Tang; Sarah Willis; Heather Jordan; Kira Villamizar; Michael Kharfen; Michael A Kolber; Allan Rodriguez; Lisa R Metsch Journal: J Acquir Immune Defic Syndr Date: 2015-12-15 Impact factor: 3.731